Illumina (Illumina) Change In Working Capital : $-90 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Illumina Change In Working Capital?

Illumina's change in working capital for the quarter that ended in Dec. 2023 was $78 Mil.

Illumina's change in working capital for the fiscal year that ended in Dec. 2023 was $-90 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Illumina Change In Working Capital Historical Data

The historical data trend for Illumina's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Change In Working Capital Chart

Illumina Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-194.00

73.00

-152.00

204.00

-90.00

Illumina Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-14.00	-195.00	26.00	1.00	78.00

Illumina Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-90 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Illumina Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Illumina's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina (Illumina) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

ILMN:Mexico 1ILMN:Italy ILU:Germany ILU:Germany ILU:Germany ILMN:Austria

Address

5200 Illumina Way, San Diego, CA, USA, 92122

Website

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Executives

Aimee L Hoyt	officer: SVP, Chief People Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jacob Thaysen	director, officer: Chief Executive Officer	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Susan H Tousi	officer: SVP Product Development	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Steven Barnard	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott B. Ullem	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Stephen P Macmillan	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Andrew Teno	director	C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Alexander Aravanis	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott D Ericksen	officer: VP, Chief Accounting Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Charles Dadswell	officer: Sr VP & General Counsel	5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank	officer: Chief Public Affairs Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo	officer: SVP Chief Medical Officer	C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carissa Rollins	officer: SVP, Chief Information Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels	officer: Chief of Global Operations	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jay T Flatley	officer: President & CEO	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121